Table 2.

Current therapy protein kinase inhibitors

Drugs	Mechanism	target	stage	Ref
Trastuzumab	Inhibits HER2	HER2	all stage	[184]
Doxorubicin	Knockdown of AMPKα1 promotes doxorubicin-induced apoptosis of breast cancer cells	AMPK α1	all stage	[228]
Lapatinib	Inhibits EGFR, HER2	EGFR, HER2	all stage	[117]
Trastuzumab	Inhibits HFR2 and HER3 dimerization, induces ADCC	HER2	all stage	[229]
Afatinib	Inhibits EGFR and HER2 signalling irreversibly	HER2/EGFR	LUX Breast1/3	[230]
Dacomitinib	Inhibits HER2, EGFR, HER4, Akt and ERK phosphorylation	EGFR, HER2, ErbB4	Phase 1B	[231]
Neratinib	Irreversibly blocks EGFR and HER2 pathway	EGFR, RET VEGFR2-3	Phase III NALA Trial	[232]
Bosutinib	inhibition of SRC-mediated signaling pathways	SRC, ABL	Phase II	[217]
Dasatinib	SRC inhibition affects P-cadherin downstream signaling	SRC	Phase I, II	[233]
Palbociclib	HR positive and EGFR negative	CDK4/6	Phase 1B	[234]
Everolimus	HR positive	mTOR	Drug resistant after metastatic	[212]
Alpelisib	HR positive	PI3K	Late stage	[235]
Olaparib	BRCA mutation	PARP	All stage	[236]